A study on Aker BioMarine Antarctic AS’s Superba Krill oil has been accepted in the journal Nutrition Research, and will be published in early 2014.
 
The study investigated the effects of Superba Krill on blood lipids in subjects with borderline high or high triglyceride levels. In terms of design, a total of 300 volunteers were divided into five groups and supplemented with krill oil at either 0.5, 1, 2 or 4 grams per day or placebo (olive oil). The subjects included in the study had blood triglyceride values between 150 and 499 mg/dL. Blood lipids were measured at baseline, 6 weeks and 12 weeks of treatment.
 
Study coordinator Kjetil Berge, PhD, R&D director, Aker BioMarine Antarctic, commented, “This is exciting because it is the biggest krill study conducted in humans to date. We look forward to sharing the full results in the coming weeks.”
 
Tove Flem Jacobsen, vice president of R&D and regulatory affairs, Aker BioMarine Antarctic added, “This study helps further document the health benefits of phospholipid-bound EPA and DHA from krill and represents an important addition to our growing research portfolio.”
 
As part of an established commitment to substantiating krill’s health benefits, Aker continues to sponsor in vitro, in vivo, and human clinical trials with phospholipid EPA and DHA from krill oil, consistently demonstrating a higher uptake of phospholipid omega 3 fatty acids, improved blood lipid profiles, and increased uptake of DHA in brain tissue.